Leukemia
Journal
Overview
publication venue for
-
Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients.
2023
-
Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.
2021
-
Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.
2021
-
Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.
2019
-
Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.
2014
-
Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide.
2005
-
Increased methotrexate polyglutamylation in acute megakaryocytic leukemia (M7) compared to other subtypes of acute myelocytic leukemia.
1997
-
The co-receptor Neuropilin-1 enhances proliferation in inv(16) acute myeloid leukemia via VEGF signaling..
39.
2024
-
The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasms..
39.
2024
-
JAK2V617F impairs lymphoid differentiation in myeloproliferative neoplasms.
2024
-
Mutation order in acute myeloid leukemia identifies uncommon patterns of evolution and illuminates phenotypic heterogeneity..
38.
2024
-
FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia..
38.
2024
-
E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial..
37.
2023
-
Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients.
2023
-
MAPK-negative feedback regulation confers dependence to JAK2V617F signaling..
37.
2023
-
SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice..
37.
2023
-
KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition..
37.
2023
-
BET inhibitors rescue anti-PD1 resistance by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8+ T cells.
2023
-
Splenomegaly (SPML) in polycythemia vera (PV): its clinical significance and its relation to symptoms, post-polycythemic myelofibrosis (PPMF) and survival.
2022
-
Recurrent germline variant in ATM associated with familial myeloproliferative neoplasms..
37.
2022
-
CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response..
37.
2022
-
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma..
37.
2022
-
MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis..
36.
2021
-
Normal life expectancy for polycythemia vera (PV) patients is possible.
2021
-
Gene therapy in a murine model of chronic eosinophilic leukemia-not otherwise specified (CEL-NOS)..
36.
2021
-
Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy..
35.
2021
-
Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans..
36.
2021
-
Gene expression derived from alternative promoters improves prognostic stratification in multiple myeloma.
2021
-
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies..
35.
2021
-
RNA-sequencing data-driven dissection of human plasma cell differentiation reveals new potential transcription regulators..
35.
2021
-
Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.
2021
-
Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia..
35.
2021
-
Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival..
35.
2021
-
Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma..
35.
2021
-
Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia..
35.
2021
-
Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target..
35.
2021
-
U2af1 is required for survival and function of hematopoietic stem/progenitor cells..
35.
2021
-
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS..
35.
2020
-
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study..
34.
2020
-
Engraftment kinetics after transplantation of double unit cord blood grafts combined with haplo-identical CD34+ cells without antithymocyte globulin..
35.
2020
-
Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response..
35.
2020
-
Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era..
34.
2020
-
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study..
35.
2020
-
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study..
34.
2020
-
The novel lncRNA BlackMamba controls the neoplastic phenotype of ALK- anaplastic large cell lymphoma by regulating the DNA helicase HELLS..
34.
2020
-
CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition..
34.
2020
-
The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment..
34.
2019
-
Prognostic impact of RAS-pathway mutations in patients with myelofibrosis..
34.
2019
-
Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications..
34.
2019
-
Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia..
33.
2019
-
Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study..
33.
2019
-
Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia..
33.
2019
-
Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia..
33.
2019
-
Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia..
33.
2019
-
A novel method for detecting the cellular stemness state in normal and leukemic human hematopoietic cells can predict disease outcome and drug sensitivity..
33.
2019
-
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance..
33.
2019
-
Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis..
33.
2019
-
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups..
33.
2019
-
Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma..
33.
2018
-
Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia..
33.
2018
-
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia..
32.
2018
-
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML..
33.
2018
-
Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma..
32.
2018
-
Rare germline variants in ATM are associated with chronic lymphocytic leukemia..
31.
2017
-
Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma..
32.
2017
-
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia..
32.
2017
-
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL..
32.
2017
-
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis..
31.
2017
-
MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs..
31.
2017
-
Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium..
31.
2017
-
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR..
31.
2016
-
Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22..
31.
2016
-
Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen..
31.
2016
-
PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies..
31.
2016
-
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma..
31.
2016
-
Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy..
31.
2016
-
Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis..
31.
2016
-
Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia..
30.
2016
-
A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis..
31.
2016
-
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study..
31.
2016
-
Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias..
31.
2016
-
DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice..
30.
2016
-
Clonal B cells in Waldenström's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling..
30.
2016
-
Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition..
30.
2016
-
Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells..
30.
2015
-
EBV-miR-BHRF1-2 targets PRDM1/Blimp1: potential role in EBV lymphomagenesis..
30.
2015
-
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides..
30.
2015
-
Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice..
30.
2015
-
BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase..
29.
2015
-
FoxO1-dependent induction of acute myeloid leukemia by osteoblasts in mice..
30.
2015
-
Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential..
29.
2015
-
Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia..
29.
2015
-
IL10 receptor is a novel therapeutic target in DLBCLs..
29.
2015
-
Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition..
29.
2015
-
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation..
29.
2014
-
Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells..
29.
2014
-
SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS..
29.
2014
-
IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia..
29.
2014
-
Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia..
28.
2014
-
Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance..
28.
2014
-
Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway..
28.
2014
-
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity..
28.
2013
-
Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia..
28.
2013
-
Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy..
28.
2013
-
Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas..
28.
2013
-
Toll-like receptor alterations in myelodysplastic syndrome..
27.
2013
-
AKT is a therapeutic target in myeloproliferative neoplasms..
27.
2013
-
JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma..
28.
2013
-
Physiologic corticosterone oscillations regulate murine hematopoietic stem/progenitor cell proliferation and CXCL12 expression by bone marrow stromal progenitors..
27.
2013
-
Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity..
27.
2013
-
Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells..
27.
2013
-
Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis..
27.
2013
-
Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety..
27.
2013
-
Cell of origin determines clinically relevant subtypes of MLL-rearranged AML..
27.
2012
-
Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis..
27.
2012
-
PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma..
27.
2012
-
MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC..
27.
2012
-
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma..
27.
2012
-
miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation..
27.
2012
-
Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells..
27.
2012
-
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study..
26.
2012
-
Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma..
26.
2012
-
Serial monitoring of human systemic and xenograft models of leukemia using a novel vascular disrupting agent..
26.
2012
-
Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications..
26.
2012
-
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia..
26.
2011
-
The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity..
26.
2011
-
The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia..
25.
2011
-
NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases..
25.
2010
-
PHF6 mutations in adult acute myeloid leukemia..
25.
2010
-
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis..
24.
2010
-
A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia..
23.
2009
-
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma..
23.
2009
-
Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells..
23.
2009
-
Monoclonal antibodies against IREM-1: potential for targeted therapy of AML..
23.
2009
-
Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics..
23.
2009
-
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates..
23.
2009
-
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis..
23.
2009
-
Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy..
23.
2009
-
Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms..
23.
2008
-
Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas..
23.
2008
-
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase..
22.
2008
-
The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab..
22.
2008
-
Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib..
22.
2008
-
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia..
22.
2008
-
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib..
22.
2008
-
Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas..
22.
2008
-
Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome..
22.
2007
-
Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo..
22.
2007
-
Genetically identical twin transplantation for chronic lymphocytic leukemia..
21.
2007
-
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations..
21.
2007
-
Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements..
21.
2007
-
The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines..
21.
2007
-
Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib..
21.
2007
-
Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma..
21.
2006
-
Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein..
20.
2006
-
Novel FISH probes designed to detect IGK-MYC and IGL-MYC rearrangements in B-cell lineage malignancy identify a new breakpoint cluster region designated BVR2..
20.
2006
-
Activation of FGFR1beta signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells..
20.
2006
-
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome..
20.
2006
-
Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation..
20.
2006
-
Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia..
19.
2005
-
KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32)..
19.
2005
-
Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate..
18.
2004
-
Deletion of 7p or monosomy 7 in pediatric acute lymphoblastic leukemia is an adverse prognostic factor: a report from the Children's Cancer Group..
18.
2004
-
Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study..
18.
2004
-
Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: possible mediation of hypoxia-inducible factor-1alpha..
17.
2003
-
A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia..
17.
2003
-
Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate..
17.
2003
-
Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity..
17.
2003
-
Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195..
17.
2003
-
Dynamics of hematopoiesis in paroxysmal nocturnal hemoglobinuria (PNH): no evidence for intrinsic growth advantage of PNH clones..
16.
2002
-
Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo..
16.
2002
-
Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies..
16.
2002
-
Transplantation of IL-2-mobilized autologous peripheral blood progenitor cells for adults with acute myelogenous leukemia in first remission..
15.
2001
-
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells..
14.
2000
-
A novel in vitro model of early human adult B lymphopoiesis that allows proliferation of pro-B cells and differentiation to mature B lymphocytes..
14.
2000
-
Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy..
14.
2000
-
Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4..
14.
2000
-
Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all-trans retinoic acid..
13.
1999
-
Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis..
13.
1999
-
A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia..
12.
1998
-
Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia..
11.
1997
-
Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia in first remission..
11.
1997
-
Rapid induction of B-cell lymphomas by avian leukosis virus..
11 Suppl 3.
1997
-
Decitabine studies in chronic and acute myelogenous leukemia..
11 Suppl 1.
1997
-
Studies of decitabine with allogeneic progenitor cell transplantation..
11 Suppl 1.
1997
-
c-kit ligand stimulates tyrosine phosphorylation of the c-Cbl protein in human hematopoietic cells..
10.
1996
-
Establishment of AIDS-related lymphoma cell lines from lymphomatous effusions..
10.
1996
-
Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice..
10.
1996
-
c-kit ligand stimulates tyrosine phosphorylation of a similar pattern of phosphotyrosyl proteins in primary primitive normal hematopoietic progenitors that are constitutively phosphorylated in comparable primitive progenitors in chronic phase chronic myelogenous leukemia..
10.
1996
-
Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia..
10.
1996
-
A pilot study of the biologic and therapeutic effects of granulocyte colony-stimulating factor (filgrastim) in patients with acute myelogenous leukemia..
9.
1995
-
Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia..
9.
1995
-
Topoisomerase II alpha gene expression in childhood acute lymphoblastic leukemia..
9.
1995
-
Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B..
9.
1995
-
Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195..
9.
1995
-
Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia..
8.
1994
-
Comparative activity of tamoxifen and N-desmethyltamoxifen in human multidrug resistant leukemia cell lines..
8.
1994
-
Combination of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle specific and cycle non-specific drugs..
8.
1994
-
Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias..
8.
1994
-
A 62-kilodalton tyrosine phosphoprotein constitutively present in primary chronic phase chronic myelogenous leukemia enriched lineage negative blast populations..
8.
1994
-
An enhanced surveillance program for adult T-cell leukemia in central Brooklyn..
8 Suppl 1.
1994
-
Phase I-II trial of high dose Ara-C, carboplatinum, etoposide and steroids in patients with refractory or relapsed lymphomas..
8.
1994
-
In vitro establishment of AIDS-related lymphoma cell lines: phenotypic characterization, oncogene and tumor suppressor gene lesions, and heterogeneity in Epstein-Barr virus infection..
7.
1993
-
Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease..
7.
1993
-
Interleukin-4 priming enhances a target for human complement-mediated cytotoxicity of CLL..
7.
1993
-
Severe toxicity limits intensification of induction therapy for acute lymphoblastic leukemia..
7.
1993
-
Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia..
6.
1992
-
Homoharringtonine is safe and effective for patients with acute myelogenous leukemia..
6.
1992
-
Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia..
5.
1991
-
Densitometric analysis of Southern blot autoradiographs and its application to monitoring patients with chronic myeloid leukemia..
5.
1991
-
Proliferative response of human acute myeloid leukemia cells and normal marrow enriched progenitor cells to human recombinant growth factors IL-3, GM-CSF and G-CSF alone and in combination..
5.
1991
-
Diffuse large cell lymphoma. Prognostic factors with treatment..
5 Suppl 1.
1991
-
Ki-1 antigen expression defines a favorable clinical subset of non-B cell non-Hodgkin's lymphoma..
4.
1990
-
Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group..
4.
1990
-
Establishment and characterization of two human myeloma cell lines secreting kappa light chains..
3.
1989
-
Analysis of the individual and combined reactivities of monoclonal antibodies H25, H366, and MY9 with normal progenitor cells and blast cells from patients with acute myeloblastic leukemia..
3.
1989
-
Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia..
3.
1989
-
Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195..
3.
1989
-
Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol..
3.
1989
-
The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia..
2.
1988
-
Patterns of T cell receptor gamma gene rearrangement and expression in B and T lymphoid malignancies..
2.
1988
-
Juvenile chronic myeloid leukemia: therapeutic insights..
1.
1987
-
Diagnosis and monitoring in patients with hairy cell leukemia using the monoclonal antibody anti-HC2..
1.
1987
-
Studies on the optimal dose and the mode of action of alpha-interferon in the treatment of hairy cell leukemia..
1.
1987
-
Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma..
33.
2019
-
A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies..
32.
2017
-
The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest..
30.
2016
-
In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche..
30.
2015
-
A unique aptamer-drug conjugate for targeted therapy of multiple myeloma..
30.
2015
-
The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma..
29.
2014
-
Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis..
29.
2014
-
Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial..
28.
2013
-
Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies..
28.
2013
-
Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance..
27.
2013
-
Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma..
26.
2011
-
Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early primary myelofibrosis..
23.
2009
-
A novel family of slitrk genes is expressed on hematopoietic stem cells and leukemias..
21.
2007
-
JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?.
20.
2006
-
BRAF gene is not mutated in plasma cell leukemia and multiple myeloma..
17.
2003
-
Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera..
17.
2003
-
Spotlight on acute promyelocytic leukemia: controversies and challenges..
16.
2002
-
Marked ploidy and BCR-ABL gene amplification in vivo in a patient treated with STI571..
15.
2001
-
Unrelated donor transplantation over the age of 55. Are we merely getting (b)older?
2005
-
Tumor evolution analysis uncovered immune-escape related mutations in relapse of diffuse large B-cell lymphoma.
2024
-
SRSF2 mutation cooperates with ASXL1 truncated alteration to accelerate leukemogenesis.
2023
-
CSF1R inhibition for histiocytic neoplasm with CBL mutations refractory to MEK1/2 inhibition.
2023
-
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.
2022
-
Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib.
2020
-
The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab.
2019
-
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.
2019
-
Risk of disease progression in low-risk MDS is linked to distinct epigenetic subtypes.
2019
-
Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma.
2019
-
Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia.
2017
-
Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial.
2016
-
Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone.
2015
-
Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia.
2015
-
Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: a report from the Children's Oncology Group.
2015
-
Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia.
2015
-
Biological properties of ligand-dependent activation of the MET receptor kinase in acute myeloid leukemia.
2014
-
Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2.
2014
-
Defined, serum-free conditions for in vitro culture of primary human T-ALL blasts.
2012
-
Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia.
2012
-
Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells.
2011
-
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine.
2011
-
DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms.
2011
-
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms.
2011
-
The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration.
2010
-
Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin's lymphoma cell lines.
2009
-
Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.
2009
-
Systematic genomic screen for tyrosine kinase mutations in CLL.
2008
-
An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia.
2008
-
Evidence suggesting the presence of a stem cell clone anteceding the acquisition of the JAK2-V617F mutation.
2008
-
Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients.
2007
-
The prevalence of IG translocations and 7q32 deletions in splenic marginal zone lymphoma.
2007
-
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.
2007
-
A PDGFRB-positive acute myeloid malignancy with a new t(5;12)(q33;p13.3) involving the ERC1 gene.
2007
-
Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation.
2007
-
NK-cell-associated receptor expression in hepatosplenic T-cell lymphoma, insights into pathogenesis.
2006
-
Ph-positive and -negative myeloproliferative syndromes may co-exist.
2004
-
Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.
2003
-
Thalidomide therapy induces response in relapsed mantle cell lymphoma.
2003
-
Clinical activity of arsenic trioxide in Burkitt-like lymphoma.
2003
-
Extensive bone marrow necrosis associated with multiple myeloma.
1999
-
Discordant erythropoiesis in CML.
1998
-
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).
2009
-
Chronic myeloid leukemia--some topical issues..
21.
2007
-
Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations.
2021
-
Genome instability in multiple myeloma.
2020
-
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
2020
-
Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.
2016
-
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.
2016
-
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).
2014
-
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.
2012
-
Predicting the effect of transcription therapy in hematologic malignancies.
2005
-
Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies.
2003
-
Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment.
1993
-
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.
2022
-
The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia.
2018
-
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.
2017
-
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG).
2013
-
Clonal evolution in hematological malignancies and therapeutic implications.
2013
-
The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics.
2012
-
Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions.
2012
-
Management of treatment-emergent peripheral neuropathy in multiple myeloma.
2011
-
Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma.
2011
-
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma.
2009
-
JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
2008
-
Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria.
2007
-
Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002.
2003
-
Allogeneic and autologous transplantation for chronic lymphocytic leukemia.
2001
-
Pediatric leukemia/lymphoma with t(8;14)(q24;q11).
1992
-
High-dose, potentially myeloablative chemotherapy and autologous bone marrow transplantation for patients with advanced Hodgkin's disease.
1989
-
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.
2009
-
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
2007
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)